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Concerns have been raised regarding the role of environmental and dietary estrogens as possible contributors to an increased incidence of various
abnormalities in estrogen-target tissues of both sexes. These abnormalities include breast cancer, endometriosis, fibroids, and uterine
adenocarcinoma in females, as well as alterations in sex differentiation, decreased sperm concentrations, benign prostatic hyperplasia, prostatic
cancer, testicular cancer, and reproductive problems in males. Whether these concerns are valid remains to be determined; however, studies with
the potent synthetic estrogen diethylstilbestrol (DES) suggest that exogenous estrogen exposure during critical stages of development can result in
permanent cellular and molecular alterations in the exposed organism. These alterations manifest themselves in the female and male as structural,
functional, or long-term pathological changes including neoplasia. Although DES has potent estrogenic activity, it may be used as a model compound
to study the effects of weaker environmental estrogens, many of which may fit into the category of endocrine disruptors. - Environ Health
Perspect 103(Suppl 7):83-87 (1995)
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Introduction
Diethylstilbestrol (DES), a potent synthetic
estrogen, was prescribed to a large popula-
tion of pregnant women to prevent miscar-
riage and other pregnancy complications.
Subsequently, it was shown that the cohort
of women exposed to DES in utero exhib-
ited a wide range of reproductive tract
abnormalities including a low, but signifi-
cantly increased, incidence ofvaginal adeno-
carcinoma (1). Likewise, it was reported
that men exposed to DES in utero experi-
enced a variety of reproductive tract prob-
lems including reduced fertility and retained
testes. Similarly, experimental animals
exposed prenatally or neonatally to DES
developed comparable genital tract alter-
ations. (Acomparison ofthe effects ofdevel-
opmental exposure to DES in humans and
mice is shown in Tables 1 and 2.) Thus, the
rodent provides an excellent model to study
the mechanisms of developmental toxicity
of estrogens. Future human risk assessment
of the deleterious effects resulting from
developmental exposure to estrogenic sub-
stances like DES will require in-depth
knowledge of mechanisms that can be
gained bystudying the rodent model.
Murine Model of
Developmental Exposure
to Diethylstilbestrol
Several murine models have been described
to study developmental exposure to estro-
genic compounds including prenatal and
neonatal exposure or a combination ofboth
treatments. Since the neonatal model is so
eloquently described by Iguchi et al. (2),
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the following description will include only
prenatal treatment. However, data obtained
from both models are important in deter-
mining cellular and molecular mechanisms.
To study the effects of prenatal expo-
sure to DES, outbred CD-1 mice were
treated sc with DES on days 9 through 16
ofgestation, the period ofmajor reproduc-
tive tract organogenesis. The doses of DES
ranged from 0.01 to 100 pg/kg during
pregnancy, equal or less than doses given
therapeutically to pregnant women. In fact,
the lower DES doses are comparable to
weaker estrogenic compounds found in the
environment. Mice were born on day 19 of
gestation, and both male and female off-
springwere followed.
To assess the effects of prenatal DES
exposure on postnatal reproductive tract
function, the fertility of DES female mice
was determined using a continuous breed-
ing protocol (3). The most striking effect
observed was a dose-related decrease in
reproductive capacity, ranging from mini-
mal subfertility at the lower DES doses to a
high frequency oftotal sterility at the high-
est DES doses (Figure 1). Over the course
of the breeding schedule, even the low
doses of DES exhibited subfertility.
Reduced reproductive capacity appeared to
be a reflection of a decrease both in the
total number oflitters and in litter sizes. A
major component of the sterility seen in
females that were given higher doses of
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Table 1. Comparative developmental effects of prena-
tal exposure to DES in the female offspring of humans
and mice.
Observed in
Developmental effect Mouse Human
Immune dysfunction + +
Mammary tumors ? ?
Ectopic pregnancy ? +
Subfertility and infertility + +
Uterine tumors + ?
Anatomical masculinization + +
Ovarian cysts + ?
Ovarian tumors + ?
Elevated serum testosterone levels ? +
Elevated testosterone secreted + ?
bythe ovary
Salpingitis isthmica nodosa of + +
oviduct
Structural abnormalities ofthe + +
uterus
Malformed cervical canal + +
Cervical and vaginal hood + +
and polyps
Vaginal adenocarcinoma + +
Vaginal adenosis + +
Persistent vaginal cornification + ?
DES was in the oviduct and ovary; the
number ofova recovered from the ampulla
of the oviduct after induced ovulation was
less than 30% that of controls. Also
observed were structural abnormalities of
the oviduct, uterus, cervix, and vagina,
which contributed to subfertility. These
data suggest that in utero exposure to DES,
even at low doses, results in the permanent
impairment of female mouse reproductive
capacity. Numerous reports of altered
pregnancy outcomes in young women
exposed in utero to DES (1), as well as
accidental DES exposure to wildlife result-
ing in infertility, demonstrate the impor-
tance ofthese findings in mice and suggest
that environmental estrogens play a role in
decreased female fertility.
To assess the long-term effects of pre-
natal DES exposure on the female, mice
were sacrificed at 12 to 18 months of age
and reproductive tract tissues were studied
for histological alterations (4). Histological
examination revealed lesions throughout
the reproductive tracts. The vagina was
characterized by excessive keratinization
and female hypospadias (urethra opens
into vagina rather than the vulva), and at
the highest dose (100 pg/kg), 5 of20 mice
had epidermoid tumors of the vagina.
Vaginal adenocarcinoma was seen in the
2.5, 5, and 10 pg/kg DES dose groups,
although its frequency was rare. The cervix
of the DES-exposed offspring was often
enlarged, but the cervical lumen was not
Table 2. Comparative developmental effects of prena-
tal exposure to DES in male offspring of humans and
mice.
Observed in
Developmental effect Mouse Human
Subfertility + +
Sperm abnormalities + +
Decreased sperm counts + +
Epididymal cysts + +
Hypoplastic and cryptorchid testes + +
Testicular tumors +
Interstitial cell tumors + ?
Seminoma + +
Rete tumors + +
Anatomical feminization + +
Microphallus + +
Hypospadias + +
Retention of MOllerian duct + +
remnants
Tumors in retained MOllerian + ?
duct remnants
Seminal vesicle tumors + ?
Prostatic inflammation + +
Prostatic tumors + ?
Immune dysfunction + ?
Skeletal changes + ?
different from controls. Stromal stimula-
tion was responsible for the enlargement in
the cervical region, and a low prevalence of
benign (leiomyoma) and malignant (stro-
mal cell sarcoma, leiomyosarcoma) tumors
was seen. Evidence of epithelial and stro-
mal stimulation in the uterine horns was
also observed, and cystic endometrial
hyperplasia was common even in the lower
DES-dose animals; a low incidence of
benign (leiomyomas) and malignant (ade-
nocarcinoma, stromal cell sarcoma) uterine
tumors was also observed. The ovaries of
prenatally DES-treated females were often
more cystic than controls; at the highest
dose (100 pg/kg), ovarian tumors were
noted and the oviducts were inflamed and
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Figure 1. Total reproductive capacity of mice exposed
prenatally to DES. Mice were CD-1 female offspring
exposed prenatally to DES on days 9 to 16.of gestation.
Postnatal fertility was determined by a repetitive
forced breeding technique and expressed as the total
number of live young born per mouse over an 8-month
(32-week) interval. The cumulative number of young
per mouse is plotted on the y-axis, while the duration
of breeding is plotted on the x-axis. Note that there is
a dose-related decrease in fertility at all DES doses
and that even the mice exposed to low doses of DES
exhibit decreased fertility as compared to correspond-
ing control mice. This figure is reproduced with permis-
sion from McLachlan et al. (3).
congenitally malformed. A summary ofthe
genital tract lesions seen in aged female
mice is shown in Table 3. These data sug-
gest that in utero exposure to DES results
in long-term consequences including an
increased risk of reproductive tract lesions.
These findings in mice may be relevant for
similarly exposed humans. For example,
the vaginal adenocarcinoma seen in mice
was similar in location and morphology to
that reported clinically in humans (1).
Table 3. Histologically diagnosed genital tract lesions in aged female mice exposed prenatally to DES.
DES dose, Abnormalities
pg/kg/day Vaginal Cervical Uterine
0
0.1 Leiomyoma
1 Papilloma
2.5 Adenocarcinoma Leiomyoma
5 Adenocarcinoma Stromal cell sarcoma Stromal cell sarcoma
10 Abnormal urethral glands Epithelial atypia Leiomyoma
Adenocarcinoma
100 Abnormal urethral glands Leiomyosarcoma Adenocarcinoma
Epidermoid tumors
Adenocarcinoma
DES, diethylstilbestrol. Females were aged offspring (12-24 months) of CD-1 mice treated sc with DES on days 9
to 16 of gestation. The prevalence of extragenital lesions was not significantly different between treatment
groups. Note that lower DES doses exhibited tumor formation. Higher doses resulted in different types of tumors
and an increased number of tumors. Data from McLachlan et al. (4) and Newbold and McLachlan (5).
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Also, the developmentally arrested murine
oviduct may be important in understand-
ing structural abnormalities in the upper
genital tract, including the T-shaped uterus
observed by hysterosalpingography in
humans (6) since both are examples of
altered development ofthe Mullerian duct.
The uterine malformation has been associ-
ated with reported menstrual irregularity
and decreased favorable pregnancy out-
come in women exposed prenatally to DES
(6-8). These findings compare similarly to
that already described for this mouse
model (3).
Effects of prenatal DES exposure on
the developing male genital tract were also
examined (9). Fertility was assessed by
breeding DES males to control female
mice of the same strain. In the prenatal
DES-exposed mouse, only the highest dose
(100 pg/kg) was associated with noticeable
changes in reproduction; 6 of 10 DES-
male offspring treated with 100 pg/kg were
sterile, while the nonsterile males had the
same breeding performance as controls
(Table 4). Several factors appeared to be
related to this decreased fertility in the
high-dose males including a) retained
testes and Mullerian remnants; b) abnor-
mal sperm morphology and motility;
c) lesions in the reproductive tract;
d) abnormal reproductive tract secretions
and; e) inflammation (9). Thus, there were
many examples of abnormalities in the
male offspring that contributed to subfer-
tility and infertility in the higher dose ani-
mals; lower dose males are currently being
evaluated for any long-term changes in
reproductive performance.
In the high-dose male DES offspring, a
long-term, rare histological alteration was
found that was apparently derived from a
change in the mesonephric epithelium.
During embryonic development, the
mesonephric duct system gives rise to the
rete testis and other male structures. The
identification of tumors in the area of the
Table 4. Effect of prenatal exposure to diethylstilbe-
strol on fertility of male offspring.
Treatment, pg/kg/day Number of sterile males
Corn oil, control 0/10
DES 0.1 0/10
DES 1 0/10
DES 10 1/10
DES 100 6/10
Males were 20- to 25-week-old offspring of pregnant
CD-1 mice treatedwith DES on days 9 to 16 ofgestation.
Nonsterile males had the same breeding performance
as controls. Data from Newbold and McLachlan (9).
rete testis is exceptionally rare; in fact, rete
testis tumors have been reported infre-
quently in the clinical literature and in
experimental animals. It is interesting that
treatment of pregnant CD-1 mice with
DES (100 pg/kg) resulted in rete testis ade-
nocarcinoma in 5% oftheir male offspring
(Table 5). The high incidence of retained
testis in mice (92%) following prenatal
DES exposure and the occurrence of the
rare rete testis adenocarcinoma raise the
possibility ofan association between prena-
tal DES exposure and the incidence of
cryptorchidism and rete testis cancer.
Although cryptorchidism resulted in
decreased or lack of spermatogenesis in
male mice, inactivity alone could not
account for the higher prevalence of rete
cancer because several ofthe mice with the
tumor had spermatogenesis occurring in
the same testis. In addition to rete cancer,
increased incidence oflesions ofthe corpus
testis and Mullerian duct remnants were
also seen (11). Since these lesions were
observed in high-dose DES males, males
receiving lower DES doses are being fol-
lowed for increased cancer risk, although
their fertilitywas not significantly affected.
Vaginal adenocarcinoma in the female
and rete testis adenocarcinoma in the male,
both extremely rare findings in experimental
animals and humans, represented only two
examples of growth-control derangements
seen as long-term defects in mice following
prenatal DES exposure. Studying alterations
in both sexes provides a better understand-
ing of the developmental events and the
mechanisms involved in decreased fertility
and increased tumor prevalence following
exposure to estrogenic compounds during
critical stages ofdevelopment.
Potential Mechanisms for
Involvement of Estrogens in
Dysregulation of Perinatal
Development
Identifying molecular and cellular targets
of estrogen in the developing reproductive
tract may help to elucidate the mechanisms
by which inappropriate exposure to estro-
genic chemicals permanently alters repro-
ductive tract growth and differentiation.
One hypothesis is that developmental
exposure to estrogen may cause the prema-
ture or permanent induction ofgenes nor-
mally under steroid control in older mature
animals. The abnormal expression ofthese
genes may contribute to the observed sub-
fertility and increased tumor occurrence in
both sexes. A recent report using the
Table 5. Testicular lesions in male mice exposed pre-
natallyto diethylstilbestrol.a
Lesion Control DES-100
Retetestis hyperplasia 23/96 (24)b 130/233 (56)*
Rete testis 0/96 (0) 11/233 (5)**
adenocarcinoma
Lesions in the testes of male mice exposed prenatally
to DES (males were 10- to 18-month-old offspring of
CD-1 mice treated with DES [100 pg/kg] on days 9to 16
of gestation). bNumbers in parentheses are percent.
Statistical significance of DES-exposed animals to cor-
responding age-matched controls by Fisher's exact test.
*p<0.0001; **p<0.05. Data from Newbold etal.(10).
murine DES model describes the persistent
expression of two estrogen-dependent
genes, lactoferrin (LF) and epidermal
growth factor (EGF), in the DES mouse
uterus and vagina (12). Earlier studies from
our laboratory described the abnormal
expression of LF in the seminal vesicle of
DES-treated male offspring (13). LF regu-
lation by estrogen has been described in
detail by Teng (14). The deregulated syn-
thesis ofthese two estrogen-inducible genes
maybe instrumental in the further develop-
ment ofgrowth and differentiation defects
and in the etiology of preneoplastic and
neoplastic lesions that are seen as long-term
consequences following developmental
estrogen exposure.
Another mechanism that may be
involved in DES-associated defects is the
estrogen receptor pathway. Reports of
humans exposed to DES suggest that the
developing fetus is extremely sensitive to
exogenous estrogens; adults, however, are
not as sensitive because treated mothers did
not develop any of the lesions observed in
their offspring. Studies with the mouse
model support the idea ofa critical exposure
period: short-term DES exposure to a
neonate results in 90% incidence ofuterine
adenocarcinoma later in life (15), but simi-
lar short-term treatment ofthe adult mouse
does not induce adenocarcinoma (Newbold
et al., unpublished data). The incidence of
uterine adenocarcinoma only reaches 1.7%
(16) in adult mice even during lifetime
exposure to DES in their diet. Certainly the
adult uterus is responsive to and stimulated
by estrogen treatment since 95% of the
mice demonstrate cystic endometrial hyper-
plasia. Spontaneous uterine adenocarcinoma
in rats is also rare and only reaches 0.5% at
2 years of age; estrogen treatment in adult
rats induces a variety ofnonneoplastic pro-
liferative lesions but cancer is rarely seen
(17). Thus, the mature, differentiated
rodent uterine epithelium responds to high
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doses of estrogen with sustained prolifera-
tion but it seldom undergoes neoplastic
transformation. This observation suggests
that the developing fetus and neonate have a
unique feature that may contribute to their
enhanced suceptibility to pertubation by
estrogens. One of the most obvious differ-
ences is the relatively low amount ofuterine
epithelial estrogen receptor in these early
stages ofdevelopment. Studies from our lab-
oratory show that developing uterine epithe-
lial cells are relatively devoid of ER while
epithelial cells ofthe oviduct and the cervix
exhibit a low, but detectable, amount ofER,
as demonstrated by immunocytochemistry
using an anti-ER monoclonal antibody
(Table 6). It is interesting to note that the
uterine tissue compartment is more sucepti-
ble to neoplastic transformation than the
oviductal or cervical compartment. Treat-
ment with DES starting on day 9 ofgesta-
tion induced the early appearance of ER in
uterine epithelial cells; the number of posi-
tive epithelial cells and staining intensity
gradually increased with age. Uterine stro-
mal cells stained for ERwere observed at all
ages examined, but staining appeared to
decrease with age in the control animals and
with DES treatment. Similar results have
been reported in male (18) and female (19)
mouse reproductive tract tissues following
neonatal exposure to DES (20). Additional
information on the role ofER in embryonic
tissues has been described by Gorski and
Hou (21). It is feasible that these fetal
epithelial ER have a physiological function
because we have demonstrated the induc-
tion of the estrogen-responsive gene for LF
in fetal uterine epithelial cells in response to
estrogens (Newbold et al., unpublished
data). It remains to be determined whether
it is the ER-induced or the ER-deficient
uterine epithelial cells that respond to DES
in an aberrant manner; however, it has been
proposed that the ER is a protective feature
and that ER-poor cells are at risk (22).
In an attempt to further study the role
of the ER in the induction of uterine
tumors following developmental exposure
to DES, transgenic mice that overexpress
ER (MT-mER) have been created (23).
These transgenic mice were treated with
DES as previously described (5). No
remarkable changes were seen in untreated
wild-type (0/10) or untreated MT-mER
(0/10) mice at 4 months ofage; DES wild-
type (10/10) and DES MT-mER (9/9)
mice showed alterations including hypo-
plastic uteri with few or no glands except
in the area of the uterine isthmus. Of
particular interest was a DES MT-mER
Table 6. Estrogen receptor immunoreactivity in epithelial cells of reproductive tracttissues of CD-1 female mice.
Control Prenatal DES-i100
Age, days Oviduct Uterus Cervix Vagina Oviduct Uterus Cervix Vagina
Fetal
13 - - -3
14 + - ++ +
15 + - + + + +b +
16 + - + +2 +b + +
17 + - + +2 +
18 + - ± +2 + + +
Neonatal
1 + - + + +2 +
4 + +b + + +3 +2 +
8 +2 +2 +2 +2
10 +4 +4 +4 +4 +4
15 +5 +5 +5 +5
17 +5 +5 +5 +5 +5 +5 +3
22 +5 +5 +5b +5b
aFemale CD-1 mice were exposed to DES on days 9 to 16 of gestation at 100 pg/kg/day. bEpithelial cells do not
exhibit homogeneous staining. All sections were incubated with an equal concentration of anti-ER monoclonal
antibody (Abbott Laboratories). A minimum of three fetuses or neonates, each from a different litter, were exam-
ined at each age. Staining intensity ranged from no staining (-), positive but weak (±), to strongly positive (+5).
Stromal staining was also observed at all ages examined but it appeared to decrease with age in the control ani-
mals and with DES treatment.
mouse (1/9) that had atypical hyperplasia in
the glands ofthe uterine isthmus. This pre-
neoplastic lesion has never been seen in sim-
ilarly treated outbred mice at this age. At 8
months ofage, the control wild-type (0/12)
and MT-mER (0/10) had no atypical
changes in the uterus, while the DES wild-
type [2/18 (11%)] and the DES MT-mER
[16/23 (70%)] had uterine adenocarcinoma.
The prevalence of this particular lesion
increased with age so that, by 12 months of
age, 78% of the DES wild-type and 100%
ofthe MT-mERmice had uterine adenocar-
cinoma. A summary of this data is seen in
Table 7. The induction ofthis lesion in this
transgenic mouse model suggests that ER
may play a role in DES toxic effects. These
results also provide support to the hypothe-
sis that the presence and levels of ER are
important factors in the initiation as well as
the maintenance ofDES-induced tumors in
Table 7. Prevalence of uterine adenocarcinoma in MT-
mER' mice following developmental treatment with
diethylstilbestrolb: preliminary data.
Treat- Age
ment Mouse 4 months 8 months 12 months
Control Wild-type 0/10 0/12 0/10
MT-mER 0/10 0/10 0/10
DES Wild-type 0/10 2/18 (11)c 7/9 (78)
MT-mER 1/9d 16/23 (70) 12/12 (100)
aTransgenic mice are overexpressing the estrogen recep-
tor; described by Davis et al. (23). bDiethylstilbestrol
treatment was on days 1 to 5 of neonatal life (2
pg/pup/day) as described by Newbold and McLachlan
(5). cNumbers in parentheses represent percent.
dPreneoplastic lesion.
the female reproductive tract. Further study
is underway to examine lesions in older
mice and to determine possible cellular
mechanisms that may be involved.
In summary, several mechanisms have
been discussed that may be involved in the
permanent induction of differentiation
defects following developmental exposure
to estrogens. This is an area that needs con-
siderably more study, but the information
that is gained will help in determining the
potential risks involved in environmental
estrogen exposure.
Conclusions
There are many possible cellular and mole-
cular mechanisms that may be involved in
the toxic response to DES and other envi-
ronmental estrogens if an organism is
exposed during critical stages of develop-
ment. Several mechanisms have been dis-
cussed in this report. Studies with the
developmentally DES-exposed murine
model have duplicated and predicted many
of the lesions seen in similarly DES-
exposed humans and in the wildlife popu-
lation. Currently, there is increased interest
in the effects ofother environmental estro-
gens and antiandrogens (24)on reproduc-
tive tract differentiation and development.
Whether these compounds have effects
similar to DES is uncertain, but since low
doses of DES demonstrate alterations in
both male and female exposed offspring,
the possibility of adverse effects from
other compounds with estrogenic and/or
antiandrogenic activity must be considered.
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